Katarzyna Wojciechowska-Durczynska

Dr. Katarzyna Wojciechowska-Durczynska

Medical University of Lodz, Łódź, Łódzkie, Poland
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
KZKatarzyna Zawadzka-Starczewska
Katarzyna Zawadzka-Starczewska
BSBartłomiej Stasiak
Bartłomiej Stasiak
KWKatarzyna Wojciechowska-Durczynska
Katarzyna Wojciechowska-Durczynska
Andrzej LewińskiAndrzej Lewiński
Andrzej Lewiński
Magdalena StasiakMagdalena Stasiak
Magdalena Stasiak
An assessment of the risk of Graves’ orbitopathy (GO) is an important challenge in Graves’ disease (GD) management. The purpose of this study was to compare non-genetic parameters in GD patients with and without GO in order to find novel risk factors and to verify the factors already reported. A total number of 161 people, 70 with GO and 91 non-GO patients were included in this study. GO was confirmed to be associated with smoking, older age, higher TSH receptor antibodies (TRAb) and lower thyroglobulin antibody (TgAb) levels and hypercholesterolemia. We demonstrated the latter correlation even for only a mild increase in LDL cholesterol. Importantly, our study provides novel potential GO risk factors, including higher serum creatinine levels, higher MCV and lower PLT. If further confirmed, these new, simple and easily accessible potential GO markers may constitute valuable auxiliary markers in GO risk assessments. We additionally proved that in moderate to severe GO, gender-related differences attenuate. No impact of vitamin D deficiency in GO development in patients with 25-hydroxyvitamin D [25(OH)D] > 20 ng/mL was found. The present report provides a set of GO risk factors, which can be used as a precise tool for an individual GO risk assessment.

1 January 2010 in Thyroid Research
Verified
Journal Article
Open access
PDF file
KWKatarzyna Wojciechowska-Durczynska
Katarzyna Wojciechowska-Durczynska
KKKinga Krawczyk-Rusiecka
Kinga Krawczyk-Rusiecka
ACAnna Cyniak-Magierska
Anna Cyniak-Magierska
AZArkadiusz Zygmunt
Arkadiusz Zygmunt
EGElżbieta Gałecka
Elżbieta Gałecka
Andrzej LewińskiAndrzej Lewiński
Andrzej Lewiński
Recent studies have shown that the phosphatidylinositol 3-kinase (PI3K) signaling pathway is important regulator of many cellular events, including apoptosis, proliferation and motility. PI3K pathway alterations (PIK3CA gene mutations and/or amplification) have been observed in various human tumours. In the majority of diagnosed cases, mutations are localized in one of the three "hot spots" in the gene, responsible for coding catalytic subunit α of class I PI3K (PIK3CA). Mutations and amplification of PIK3CA gene are characteristic for thyroid cancer, as well.

10 January 2011 in Thyroid Research
Verified
Journal Article
Open access
PDF file
ACAnna Cyniak-Magierska
Anna Cyniak-Magierska
KWKatarzyna Wojciechowska-Durczynska
Katarzyna Wojciechowska-Durczynska
KKKinga Krawczyk-Rusiecka
Kinga Krawczyk-Rusiecka
AZArkadiusz Zygmunt
Arkadiusz Zygmunt
Andrzej LewińskiAndrzej Lewiński
Andrzej Lewiński
Background: RET/PTC rearrangements are the most frequent molecular changes in papillary thyroid carcinoma (PTC). So far, 15 main RET/PTC rearrangements have been described, among which RET/PTC1 and RET/PTC3 are the most common in PTC - especially in radiation-induced tumours. RET/PTC1 and RET/PTC3 are the result of intrachromosomal paracentric inversions in chromosome 10, where RET and the activating genes (H4 and ELE1, respectively) are located. Recently, RET/PTC rearrangements have been shown not only in PTC but also in benign thyroid lesions, including Hashimoto's thyroiditis (HT). The aim of study was an assessment of RET/PTC1 and RET/PTC3 rearrangements in patients with Hashimoto's thyroiditis. Materials and methods: Thyroid aspirates, eligible for the study, were obtained from 26 patients with Hashimoto's thyroiditis by fine-needle aspiration biopsy (FNAB). Each aspirate was smeared for conventional cytology, while its remaining part was immediately washed out of the needle. The cells, obtained from the needle, were used in further investigation. Total RNA from FNAB was extracted by use of an RNeasy Micro Kit, based on modified Chomczynski and Sacchi's method and reverse transcription (RT-PCR) was done. Quantitative evaluation of RET/PTC1 and RET/PTC3 rearrangements by real-time PCR was performed by an ABI PRISM® 7500 Sequence Detection System. In the study, PTC tissues with known RET/PTC1 and RET/PTC3 rearrangements served as a reference standard (calibrator), while β-actin gene was used as endogenous control. Results: Amplification reactions were done in triplicate for each examined sample. No RET/PTC1 and RET/PTC3 rearrangements were found in the examined samples. Conclusions: Our results indicate that RET/PTC1 and RET/PTC3 rearrangements in Hashimoto's thyroiditis, if any, are rather rare events and further investigations should be conducted in order to determine molecular changes, connecting Hashimoto's thyroiditis with PTC.

17 December 2014 in Thyroid Research
Verified
Journal Article
Open access
PDF file
KKKinga Krawczyk-Rusiecka
Kinga Krawczyk-Rusiecka
KWKatarzyna Wojciechowska-Durczynska
Katarzyna Wojciechowska-Durczynska
ACAnna Cyniak-Magierska
Anna Cyniak-Magierska
AZArkadiusz Zygmunt
Arkadiusz Zygmunt
Andrzej LewińskiAndrzej Lewiński
Andrzej Lewiński
The cyclooxygenases are a group of enzymes catalyzing the formation of prostaglandins from arachidonic acid. Cyclooxygenase-1 (COX-1) is a constitutive form, thought to be a “housekeeping gene”, with constant levels of expression in most tissues. COX-1 expression in the thyroid gland, except for medullary thyroid carcinoma, has not been a subject of much interest. Cyclooxygenase-2 (COX-2) can be expressed in response to various stimuli, such as mitogens, hormones, cytokines, growth factors. The product of COX-2 activity has been implicated in carcinogenesis. Recent studies have shown that up-regulation of COX-2 is associated with numerous neoplasms. Hereby, we present a study analysing COX-1 and COX-2 expression in papillary thyroid carcinoma (PTC), Hashimoto thyroiditis (HT) and nontoxic nodular goitre (NNG) in fine needle aspiration biopsy (FNAB) washouts and in postoperative tissue. Cytological specimens from 120 patients (105 females and 15 males) have been studied, including patients with HT, PTC and NNG. Moreover, we have examined postoperative tissue specimens from 51 patients with PTC and NNG. The methods of molecular analysis have included extraction of total RNA from FNAB cytological material and postoperative tissues, spectrophotometric assessment of the RNA purity, cDNA synthesis in reverse transcription reaction and an analysis of genes expression data by real-time PCR. The performed analysis has revealed statistically significant higher expression level of the COX-2 gene in PTC group, in comparison with HT and NNG groups (in both cytological and postoperative material). In PTC patients, COX-2 gene expression levels in the material obtained by FNAB were similar to those in the postoperative thyroid tissue. No correlations between COX-2 gene expression level and TNM staging in PTC samples have been observed. There were no correlations between COX-2 expression and anti-TPO antibodies level, or patient’s sex or age in the studied groups. Also, there were no correlations of COX-1 gene expression level among PTC, HT and NNG groups. Our results suggest that COX-2 gene does not participate in the mechanisms involved in molecular association of HT with PTC. However, in case of PTC itself, it may play some role in neoplastic transformation.

10 January 2011 in Thyroid Research
Verified
Journal Article
Open access
PDF file
KKKinga Krawczyk-Rusiecka
Kinga Krawczyk-Rusiecka
KWKatarzyna Wojciechowska-Durczynska
Katarzyna Wojciechowska-Durczynska
ACAnna Cyniak-Magierska
Anna Cyniak-Magierska
ZAZbigniew Adamczewski
Zbigniew Adamczewski
EGElżbieta Gałecka
Elżbieta Gałecka
Andrzej LewińskiAndrzej Lewiński
Andrzej Lewiński
Background: COX-2 is an enzyme isoform that catalyses the formation of prostanoids from arachidonic acid. An increased COX-2 gene expression is believed to participate in carcinogenesis. Recent studies have shown that COX-2 up-regulation is associated with the development of numerous neoplasms, including skin, colorectal, breast, lung, stomach, pancreas and liver cancers. COX-2 products stimulate endothelial cell proliferation and their overexpression has been demonstrated to be involved in the mechanism of decreased resistance to apoptosis. Suppressed angiogenesis was found in experimental animal studies as a consequence of null mutation of COX-2 gene in mice. Despite the role of COX-2 expression remains a subject of numerous studies, its participation in carcinogenesis or the thyroid cancer progression remains unclear. Methods: Twenty three (23) patients with cytological diagnosis of PTC were evaluated. After FNAB examination, the needle was washed out with a lysis buffer and the obtained material was used for COX-2 expression estimation. Total RNA was isolated (RNeasy Micro Kit), and RT reactions were performed. β-actin was used as endogenous control. Relative COX-2 expression was assessed in real-time PCR reactions by an ABI PRISM 7500 Sequence Detection System, using the ΔΔCT method. Results: COX-2 gene expression was higher in patients with PTC, when compared to specimens from patients with non-toxic nodular goitre (NTG). Conclusions: The preliminary results may indicate COX-2 role in thyroid cancer pathogenesis, however the observed variability in results among particular subjects requires additional clinical data and tumor progression analysis.

KWKatarzyna Wojciechowska-Durczynska
Katarzyna Wojciechowska-Durczynska
AZArkadiusz Zygmunt
Arkadiusz Zygmunt
MMMarta Mikulak
Marta Mikulak
MLMarta Ludwisiak
Marta Ludwisiak
Andrzej LewińskiAndrzej Lewiński
Andrzej Lewiński
Gorham-Stout disease (GSD) is a very rare, life-threatening condition characterized by the proliferation of lymphatic vessels and osteolysis. Unfortunately, no standard treatment has been determined for management of GSD. The available therapies are not equally effective and carry substantial side-effects. We report a 42-year-old female with GSD manifested in multifocal osteolysis and chronic chylothorax and ascites. The combined treatment with sirolimus and zoledronic acid due to its synergism of action was introduced. To our knowledge, this is the first Polish case report of adult patients with Gorham-Stout disease.